May 20 (Reuters) - Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter.

A sale could value Amoun at $700 million to $800 million, Bloomberg reported.

Valeant was not immediately available for comment.

Should Amoun fail to find a buyer, it may consider an initial public offering in London, the report said.

Amoun could not be immediately reached for comment.

(Reporting by Rosmi Shaji in Bengaluru; Editing by Sriraj Kalluvila) ((Rosmi.Shaji@thomsonreuters.com;)(Within U.S.+1 646 223 8780 and outside U.S.)(+91 8067496753)(; Reuters Messaging: rosmi.shaji.thomsonreuters.com@reuters.net))

Keywords: AMOUNPHARMACEUTICALCO M&A/VALEANT PHARMS